The company’s oral, microbiome-changing therapy was well tolerated in patients with amyotrophic lateral sclerosis.

The announcement means the company will be pulling the plug on the CardinALS trial after its amyotrophic lateral sclerosis ...

MaaT Pharma Announces Positive Phase 1b Results, Meeting Primary Endpoint in the Evaluation of MaaT033 in Amyotrophic Lateral ...

MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival ...

MaaT Pharma’s quest to bring a microbiota-based therapy to market has moved a step forward with new data showing a benefit for its MaaT013 candidate in an early-access programme (EAP).

LYON, France--(BUSINESS WIRE)--Regulatory News: MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem ...

View upcoming earnings forecasts and in-depth analysis of company forecasts.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Maat Pharma is listed on the Euronext Paris trading with ticker code MAAT.PA. It has a market capitalisation of €108.84m, with approximately 13.92m shares in issue. Over the last year ...

French-based MaaT Pharma is eyeing up a Phase II study of its immune system modulator after its Phase Ib trial in patients with amyotrophic lateral sclerosis (ALS) met all of its primary endpoints.

LYON, France--(BUSINESS WIRE)--Regulatory News: MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem ...